Advertisement
Advertisement
U.S. markets close in 1 hour 6 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.69-0.22 (-2.22%)
As of 02:54PM EST. Market open.
Advertisement
Sign in to post a message.
  • M
    Mannan
    I never thought we would ever see low 10s again. Wow.
  • B
    Boby
    why it is down after market 22%?
  • A
    Archimedes
    As posted by jesus, there was only one share traded at $10.12 and that happened late in AH on Thursday. Meanwhile ~ 7,000 shares were traded at $13.01 in the first couple of minutes of AH.

    https://www.nasdaq.com/market-activity/stocks/atha/after-hours-trades
    Bullish
  • C
    Cured
    $SLS conversation
    $SLS to Report Identical Twin Trial to $GLSI results that Launched it 2,000% in a day Immuno SABC Data
    So Thursday NPS News? Prof. Mittendorf will attend and discuss ‘Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches’ SABC Symposium 2021 (7-10 Dec 2021): Spotlight Session https://www.sabcs.org/Program/Daily-Schedule/Day-3 Poster Session 4 Hall 1 (from 5.00 to 6.30 PM)
    The website https://clinicaltrials.gov/ct2/show/NCT02297698 [Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+)] indicates ‘Estimation primary completion date is December 2021’ - Prof Peoples and Mittendorf work specifically on the GLSI trial too (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188712/)

    $MRKR $GLSI, $XbI Free Money $IMMP $IMGN $ATHA $MGTX
    Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients - Full Text View.
    Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients - Full Text View.
    clinicaltrials.gov
  • Y
    Yahoo Finance Insights
    Athira Pharma is up 7.71% to 10.77
  • J
    JimmyMac
    Anyone know what’s driving this slide? General sentiment or something coming out?
  • B
    Bert
    Well, this is my only green one in my portfolio. LOL
  • S
    Sandra
    The pipeline review was well received. Kept ATHA in the green on a very red day.
  • Y
    Yahoo Finance Insights
    Athira Pharma is down 6.92% to 11.83
  • Y
    Yahoo Finance Insights
    Athira Pharma is down 7.24% to 11.14
  • M
    Mannan
    Oh please. Not again. If it's just a glitch I am buying at the market open.
  • s
    student
    Top Institutional Holders

    Holder Shares Date Reported % Out Value
    Perceptive Advisors Llc 3,425,916 Sep 29, 2021 9.17% 32,135,092
    Franklin Resources, Inc. 2,082,920 Sep 29, 2021 5.58% 19,537,789
    Blackrock Inc. 2,008,903 Sep 29, 2021 5.38% 18,843,510
    RTW Investments LP 1,906,557 Sep 29, 2021 5.10% 17,883,504
    Logos Global Management LP 1,855,812 Sep 29, 2021 4.97% 17,407,516
    Vanguard Group, Inc. (The) 1,641,483 Sep 29, 2021 4.39% 15,397,110
    VR Adviser, LLC 1,196,196 Sep 29, 2021 3.20% 11,220,318
    Pathstone Family Office, Llc 1,146,447 Sep 29, 2021 3.07% 10,753,672
    Citadel Advisors LLC 1,135,549 Sep 29, 2021 3.04% 10,651,449
    Wasatch Advisors Inc 896,283 Sep 29, 2021 2.40% 8,407,134
  • S
    Sandra
    Long ATHA. Is anyone also following IMAB for its Protollin nasal spray?
  • Y
    Yahoo Finance Insights
    Athira Pharma is up 7.34% to 15.95
  • B
    Bert
    I see us slowly moving upwards as they are coming with results in thd first half of next year. They seem to be on track.
    Bullish
  • Y
    Yahoo Finance Insights
    Athira Pharma is down 6.93% to 12.08
  • Y
    Yahoo Finance Insights
    Athira Pharma is down 6.79% to 12.50
  • Y
    Yahoo Finance Insights
    Athira Pharma is up 7.50% to 13.91
  • D
    Dick
    I can't wait till next week this is going to be the easiest money we all ever made
  • B
    Bob
    Big gamble here could pay off huge if results are positive, look at SAVA and ANVS, it's all about results.
    This CEO stuff is a side show that has shaken confidence. Does her reasearch have anything to do with the company research? If it does not than this drop is much to do about nothing.
Advertisement
Advertisement